Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
CP-24879 hydrochloride (CP24879; p-isopentoxyaniline)) is a novel and potent dual inhibitor of D5D/D6D (delta5 and/or the delta6) fatty acid desaturase with antisteatotic and anti-inflammatory activity. Reduced levels of arachidonic acid (AA; 20:4 n-6) are thought to be the cause of the anti-inflammatory effects of essential fatty acid deficiency or n-3 polyunsaturated fatty acid supplementation. Decreased endogenous synthesis of AA could be achieved by selectively inhibiting the delta5 and/or delta6 fatty acid desaturases, which is an alternative and logical method of AA depletion. Inflammatory damage and intracellular lipid buildup in hepatocytes can both be significantly reduced by CP-24879 treatment.
Targets |
delta6D in ABMC-7 cells (IC50 = 0.015 μM); delta6D in Liver microsomes (IC50 = 0.56 μM); delta5D in ABMC-7 cells (IC50 = 0.67 μM); delta5D in ABMC-7 cells (IC50 = 3.4 μM)
|
---|---|
ln Vitro |
CP-24879 (hydrochloride) (0-10 μM, 4 days) inhibits Δ6 + Δ5 desaturase activities in a concentration-dependent manner, with a concentration-dependent depletion of AA and a reduction in LTC4 production[1].
CP-24879 (hydrochloride) (0-10 μM, 16 h) exhibits inhibitory effects on triglyceride accumulation brought on by oleic acid in hepatocytes[2]. In a concentration-dependent manner, CP-24879 (hydrochloride) ((0-10 μM, 16 h) inhibits LPS-induced expression of inflammatory cytokines[2]. CP-24879 (hydrochloride) (0-2 μM, 4 h) inhibits desaturase activity and ameliorates ferroptosis[3]. |
ln Vivo |
CP-24879 (hydrochloride) (3 mg/kg, IP, three times per day, for six or four days) inhibits Δ6 + Δ5 desaturase activities in vivo, depleting AA in the livers of mice fed chow while preventing repletion in the livers of mice with EFAD[1].
CP-24879 (hydrochloride) (33 mg/kg, IV, once) is cleared quite quickly and has a relatively short half-life[1]. |
References |
|
Molecular Formula |
C11H18CLNO
|
---|---|
Molecular Weight |
215.721
|
Exact Mass |
215.1077
|
Elemental Analysis |
C, 61.25; H, 8.41; Cl, 16.43; N, 6.49; O, 7.42
|
CAS # |
10141-51-2
|
Related CAS # |
10141-51-2
|
Appearance |
Solid powder
|
SMILES |
CC(C)CCOC1=CC=C(C=C1)N.Cl
|
InChi Key |
GFESZSNFRSACMU-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C11H17NO.ClH/c1-9(2)7-8-13-11-5-3-10(12)4-6-11;/h3-6,9H,7-8,12H2,1-2H3;1H
|
Chemical Name |
4-(3-methylbutoxy)aniline;hydrochloride
|
Synonyms |
CP 24879 hydrochloride; CP24879 hydrochloride; CP-24879 hydrochloride
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~43 mg/mL (~199.3 mM)
Ethanol: ~43 mg/mL (~199.3 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.6356 mL | 23.1782 mL | 46.3564 mL | |
5 mM | 0.9271 mL | 4.6356 mL | 9.2713 mL | |
10 mM | 0.4636 mL | 2.3178 mL | 4.6356 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Inhibition of desaturase activity by SC-26196 or CP-24879 ameliorates ferroptosis. Proc Natl Acad Sci U S A . 2020 Dec 22;117(51):32433-32442. td> |